Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company committed to merging traditional therapeutics with psychedelic research to address a variety of underserved conditions. The company's focus spans post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer's disease, Parkinson's disease, and other rare neurological disorders.
Silo's mission is to identify and license transformative assets, funding cutting-edge research to enhance patient well-being and advance the healthcare industry. Recent achievements include the filing of a provisional patent for SP-26, a ketamine-based implant for chronic pain management, and the exclusive licensing of SPC-15 from Columbia University, a novel intranasal treatment for PTSD and anxiety.
Core Business and Projects
- SPC-15: An intranasal treatment targeting PTSD and stress-induced anxiety disorders. Silo has exercised its option to license SPC-15 from Columbia University, with preclinical studies showing promising results.
- SP-26: A time-release, ketamine-loaded implant aimed at fibromyalgia and chronic pain relief. The implant has shown positive results in pre-clinical studies and is expected to be the first at-home approved ketamine-based therapeutic if it passes clinical trials.
- SPC-14: An intranasal compound for the treatment of Alzheimer's disease, showing potential in preclinical studies for improving cognitive function and stress reduction.
- SPU-16: A CNS-homing peptide targeting multiple sclerosis (MS), developed in collaboration with the University of Maryland, Baltimore.
Silo's innovative approach combines traditional therapies with psychedelic treatments, aiming to develop novel formulations and drug delivery systems. The company's robust pipeline and strategic partnerships with leading medical universities position Silo at the forefront of biopharmaceutical advancements.
Financial Condition and Partnerships
Silo Pharma collaborates extensively with Columbia University and the University of Maryland, Baltimore, providing essential financial resources to advance their research from the clinical stage to commercialization. The company is financially positioned to support ongoing and future projects that could significantly impact the medical and psychedelic treatment landscape.
For more information, visit www.silopharma.com and connect on social media at LinkedIn, X, and Facebook.
Silo Pharma has secured an exclusive, global license with Columbia University to develop SPC-15, an intranasal treatment for PTSD and stress-induced anxiety disorders. The agreement includes extensive issued and pending IP patent applications. Silo has submitted a pre-IND briefing package to the FDA and is preparing for an IND application to begin human clinical trials. The company plans to use the FDA's 505(b)(2) pathway to expedite development and reduce costs. CEO Eric Weisblum emphasizes that this agreement could potentially increase shareholder value, contingent on FDA approval.
Silo Pharma (Nasdaq: SILO), a biopharmaceutical company, has partnered with AmplifyBio to conduct a GLP study for SPC-15, an intranasal treatment for PTSD and anxiety. This study aims to evaluate the safety and efficacy of SPC-15 over a 28-day period, following positive results from earlier non-GLP studies. The company's goal is to secure FDA approval for first-in-human trials. If successful, this will mark a significant milestone for Silo Pharma's development strategy.
Silo Pharma announced the successful production of its SP-26 ketamine implant designed for fibromyalgia and chronic pain. Analytical testing confirmed optimal formulation, with pre-clinical research ongoing. Small batch proof-of-concept extrusion trials for 20% and 40% ketamine hydrochloride loads showed validation in structural stability and integrity. Manufacturing studies using three bioresorbable polymers revealed positive data for inherent viscosity, blend uniformity, and dissolution, meeting FDA guidelines. CEO Eric Weisblum stated that these findings bring Silo closer to future pre-clinical testing models, highlighting the implant's promising structural stability and functionality.
Silo Pharma, a developmental stage biopharmaceutical company, announced the closing of its $2 million registered direct offering priced at-the-market under Nasdaq rules. The offering included 917,432 shares of common stock at $2.18 per share. Concurrently, Silo issued unregistered warrants to purchase up to 917,432 shares at $2.06 per share. These warrants are immediately exercisable and will expire in five years. H.C. Wainwright & Co. acted as the exclusive placement agent. Gross proceeds were approximately $2 million before fees and expenses. The net proceeds will be used for working capital and general corporate purposes.
Silo Pharma (Nasdaq: SILO), a developmental stage biopharmaceutical company, announced a $2 million registered direct offering of 917,432 shares of common stock at $2.18 per share, set to close on June 6, 2024. Concurrently, the company will issue unregistered warrants to purchase 917,432 shares of common stock at an exercise price of $2.06 per share. H.C. Wainwright & Co. acts as the exclusive placement agent. The proceeds will support working capital and corporate purposes. The offering is under a 'shelf' registration statement on Form S-3 effective since January 30, 2024. The warrants and underlying shares remain unregistered under the Securities Act of 1933.
Silo Pharma has submitted a pre-Investigational New Drug (pre-IND) application to the FDA for SPC-15, its intranasal treatment for PTSD and anxiety. The application seeks guidance for initiating first-in-human trials. Preclinical studies show positive results, with effective intranasal delivery in animal models. Silo expects to finalize an exclusive license agreement with Columbia University for SPC-15 by mid-2024. The company plans further studies in 2024, essential for future IND submission. SPC-15 aims to enhance stress resilience, differing from existing PTSD treatments that mainly address depressive symptoms.
Silo Pharma announced promising results from a study on depression treatment and relapse prevention. This study, in collaboration with Columbia University, identified a new drug formulation that significantly improves mood stability without common side effects of current antidepressants. CEO Eric Weisblum emphasized the potential impact on millions suffering from depression. Additionally, Silo is advancing its SPC-15 program for PTSD, with plans to submit a pre-IND to the FDA. The company is finalizing an exclusive license agreement to develop and commercialize SPC-15 globally, expected to complete in the first half of 2024.
Silo Pharma, a developmental stage biopharmaceutical company, will attend a hybrid public meeting hosted by the FDA and Reagan-Udall Foundation on June 27, 2024. The event, titled “Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest,” will discuss ketamine's use for treating depression and chronic pain. CEO Eric Weisblum, along with a scientific advisor, will represent Silo Pharma. The company's lead program, SPC-15, is an intranasal treatment for PTSD and anxiety, licensed exclusively from Columbia University. Additionally, Silo is developing SP-26, a ketamine-based dissolvable implant for chronic pain and fibromyalgia.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
What does Silo Pharma, Inc. specialize in?
What are Silo Pharma's leading development programs?
Who are Silo Pharma's research partners?
What recent achievements has Silo Pharma announced?
How does Silo Pharma aim to impact the healthcare industry?
Where can I find more information about Silo Pharma?
What is the significance of Silo Pharma's SP-26 program?
What progress has been made with the SPC-15 program?
What conditions does Silo Pharma aim to address with its treatments?
How does Silo Pharma fund its research projects?
